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Introduction 
Multiple myeloma (MM) is a hematological disorder 
caused by the emergence of a malignant clone of 
plasma cells, a mature form of B lymphocytes. The 
disease is frequently preceded by a phase of mono-
clonal gammopathy characterized by the presence of 
a paraprotein in the serum of the patients, but without 
signs or symptoms of illness. Since 1 - 2%!yea r of the 
patients with paraproteinemia develop MM, most 
authors use the term "monoclonal gammopathy of 
unknown significance" (MGUS). 
In order to get clinically relevant indicators for the 
prognosis and treatment of myeloma patients, Durie 
and Salmon established a staging system which cor-
relates well with the estimated total number of malig-
nant cells (1) . Additional factors were found to cor-
relate with the prognosis, e. g .. the labeling index 
indicating the percentage of proliferating plasma cells 
in the bone marrow (2) , and the serum concentration 
of beta-2-microglobulin, which has been shown to be 
produced by myeloma cultures in vitro (3,4). 
D-erythro-neopterin is secreted by monocytes/mac-
rophages upon stimulation with interferon gamma (5). 
Thi s effect can be synergistically enhanced by tumor 
necrosis factor alpha (6). Neopterin has been shown 
to be of prognostic value in Hodgkin's disease, non-
Hodgkin's lymphoma and chronic myelogenous leu-
kemia (7, 8). 
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The aim of this study was to analyse the diagnostic 
value of urinary neopterin in patients . with MGUS 
and multiple myeloma. 
Patients and Methods 
PUlien lS 
51 patients were included in this study. All of them 
had monoclonal gammopathy confirmed by immu-
noelectrophoresis of serum and/or urine. 41 patients 
(80%) suffered from MM , 10 patients had MGUS. 
MM was excluded in these patients by bone marrow 
examination « 10% plasma cells), bone radiography 
(lack of osteolytic lesions) and a stable course of the 
myeloma-protein. Staging of MM was performed ac-
cording to the sys tem of Salmon and Durie (1). 
Characteristics of patients are summarized in Table 
1. None of the patients with MGUS was treated. Out 
of the patients with MM , 10/41 were evaluated at the 
time of diagnosis, 8/41 had no treatment because of 
remission or stable disease. The other 23 were under 
Table I . Characteristics of patients 
Patients 







n = 51 
65 (range 37 - 86) 
29: 22 
10 (19.6°;;,) 





chemotherapy for active disease and determination of 
neopterin was Llsually performed four weeks after last 
therapy. 
Analytical procedures 
Hemoglobin and leukocytes were routinely evaluated 
from fresh blood samples using a cell counter (Coul-
ter, Miami, FL USA). Differential counts were done 
by examination of stained blood smears. Beta-2-mi-
croglobulin was measured using a commercially avail-
able radioimmunoassay (Pharmacia, Uppsala, Swe-
den). Neopterin was determined by an optimized and 
fully automated high pressure liquid chromatography 
technique without previous oxidative treatment as 
described elsewhere (9). By this reverse-phase tech-
nique, urinary creatinine is simultaneously determined 
in the same urine specimen. To account for variations 
of urine concentrations, neopterin levels are expressed 
as I1mol /mol creatinine. 
Statistics 
For the evaluation of differences between various 
groups of patients we used Kruskal-Wallis rank sum 
test. To define the strength and significance of cor-
relations we computed Spearman's rank correlation 
coefficients. 
Results 
Neop/erin. hct{{-:2-microglobllIiJl {{nd hema/ological val-
lies (Table :2) 
Neopterin and beta-2-microglobulin 
In MGUS patients the mean neopterin value was 
below the upper normal limit. In contrast, in MM 
patients the mean value was clearly elevated. Due to 
the high standard deviations, the difference between 
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MGUS and MM did not reach statistical significance 
(p = 0.119). Comparing patients with MGUS and 
MM stage I (mean value 199 ± 86) with patients 
showing M M stage II / Ill (362 ± 249) the difference 
was statistically significant (p = 0.(06) . Beta-2-mi-
croglobulin concentrations in the serum were higher 
in patients with M M stage II / III than in patients with 
MGUS and MM stage I (p < 0.05). 
Hemoglobin, monocytes and peripheral lymphocytes 
Hemoglobin concentrations and total number of pe-
ripheral lymphocytes were significantly lower in M M 
of advanced stage than in MGUS and stage I MM 
(p < 0.001 and p = 0.035 , respectively) , whereas the 
number of peripheral monocytes was not different 
(p = 0.388). 
Correlation hetll'ccn I1coprerin . heta-2-nzicroglobulin 
{lnd hematological paramerers 
Correlating neopterin with the other values we found 
a significant negative correlation between neopterin 
and the hemoglobin concentrations (r = -0.542, 
p = < 0.05). A positive correlation was seen between 
neopterin and the number of peripheral monocytes 
(r = 0.38, p < 0.05), whereas a correlation with lym -
phocytes was not found. Beta-2-microglobulin cor-
related with hemoglobin values in a similar manner 
as neopterin (r= -0.702, p= <0.01). Finally we 
observed a significant positive correlation between 
neopterin and beta-2-microglobulin (r = 0.53, 
p < 0.05) . 
Discussion 
Our data show elevated concentrations of urinary 
neopterin and beta-2-microglobulin in patients with 
MM, especially in patients with more advanced dis-
Table 2. Urinary neopterin. beta-2-microglobulin and hematological parameters in patients with MGUS and multiple myeloma 
Neopterin 
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MGUS 
200 ± 107 
3. 1 ± 2.8 
14.7 ± 1.1 
2139 ± 575 
660 ± 322 
Myeloma p 
318 ± 227 0. 119 
8.0 ± 9.8 <0.050 
11.8 ± 2.5 0.001 
1363 ± 675 0.002 
477 ± 339 0.132 
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ease. Similar results havc been described by others 
(10 - 12). From our data the question remains open. 
if neopterin is of special va lue in the differential di-
agnosis between MG U S and MM. since we havc 
found similar values in MGUS and MM stage l. 
Nevertheless, increased va lues renect a significant ac-
tivity of the disease and may represent an additional 
parameter, e. g., for the deci sio n if therapy is necessary 
or not. 
The close correlation between neopterin and beta-2-
microglobulin argues in favor of a similar clinical 
relevance of both markers. additionally neopterin is 
not dependent on the renal function. since neopterin 
values arc related to urinary creatinine. Thomas (11 ) 
found that urinary neopterin concentrations correla te 
even stronger with the calculated tumor cell mass tha n 
beta-2-microglobulin . 
Previous results have shown a negative correlation 
between hemoglobin and neopterin values (13) point-
ing to a potential role of immunological factors in the 
pathogenesis of anemia in hematological disorders . 
These data have been confirmed also in the present 
analysis of patients with \1 GU S and MM. Anemia 
in these patients might be not only due to bone 
marrow replacement. bu t mediated by a number of 
cytokines. e. g., interfero n gamma or tumor necrosis 
factor, although we found a correlation between the 
degree of bone marrow infi ltration by plasma cells 
and that of anemia (data not shown). 
Elevated neopterin values are a sign of activation of 
ccll mediated immunity. Therefore our data raise the 
question . whether the monocyte/ macrophage system 
is activated in the framework of an - ineffective -
immune reaction against the tumor or whether ele-
vated neopterin concentrations result from macro-
phage activation by cytokines produced by the mali g-
nant cells themselves . 
These two aspects . the clinical relevance on the one 
hand and the expression of an activation status of 
monocytes!macrophages on the other hand. ma ke 
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